Published in Br J Cancer on July 29, 2014
fMiRNA-192 and miRNA-204 Directly Suppress lncRNA HOTTIP and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma. PLoS Genet (2015) 1.69
Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model. J Hepatol (2014) 1.50
Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol (2015) 1.17
A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis. Oncotarget (2017) 0.79
Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients. J Transl Med (2015) 0.79
Targeting β-catenin in hepatocellular cancers induced by co-expression of mutant β-catenin and K-Ras in mice. Hepatology (2016) 0.75
Glucose-dependent anaplerosis in cancer cells is required for cellular redox balance in the absence of glutamine. Sci Rep (2016) 0.75
Drug-induced amino acid deprivation as strategy for cancer therapy. J Hematol Oncol (2017) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol (2000) 29.28
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A (2007) 15.88
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A (2008) 11.71
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci U S A (2011) 3.39
Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis (2013) 3.07
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol (2009) 2.33
Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology (2011) 2.33
New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene (2002) 2.23
Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol (2010) 1.91
Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol (2009) 1.85
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia (2007) 1.51
Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology (2009) 1.31
Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene (1999) 1.22
Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest (1988) 1.18
Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res (2006) 1.08
Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res (2010) 1.04
Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J (2001) 1.02
R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol (2006) 1.02
Liver tumors in children. Pediatr Transplant (2004) 0.99
Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer Res (2012) 0.97
L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets (2011) 0.96
Expanding targets for a metabolic therapy of cancer: L-asparaginase. Recent Pat Anticancer Drug Discov (2012) 0.92
Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS One (2012) 0.92
Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells. Cell Physiol Biochem (2005) 0.91
Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer (2013) 0.88
Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma. PLoS One (2012) 0.85
The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase. Cancer Chemother Pharmacol (2007) 0.84
Glutamine stimulates mTORC1 independent of the cell content of essential amino acids. Amino Acids (2012) 0.83
The non-proteinogenic amino acids L-methionine sulfoximine and DL-phosphinothricin activate mTOR. Amino Acids (2011) 0.81